Funny how both $JNJ and $AZN have experienced trial-holding clinical outcomes. Both also happen to be adenovirus-vector vaccines. 🤔Transverse myelitis is no joke. Feel free to come join us over at $BNTX! Over 31,000 people have already completed their 2-dose vaccine course, with no serious events. An interim analysis of efficacy is expected any day, and $BNTX is currently on track to be the first vaccine provider across the finish line if the P3 results are positive.